About Us
TWi USA
USA Team
Our Products
For Customers
Authorized Distributors
TWi USA State Licenses
Return Goods Policy
Customer Service Contacts
For Patients
Adverse Event Reporting, Product Complaints & Medical Information(FOr USA Only)
Sorafenib Co-Pay Savings Program
Contact Us
buPROPion Hydrochloride Extended-Release Tablets (XL)
Cyclobenzaprine Hydrochloride Extended-Release Capsules
Diltiazem Hydrochloride Extended-Release Capsules
Dimethyl Fumarate Delayed-Release Capsules
Donepezil tablets
Fenofibric Acid Delayed-Release Capsules
Fluphenazine Hydrochloride Tablets, USP
Guanfacine Hydrochloride Extended-Release Tablets
Hydroquinone Cream
MegestrolAcetate Oral Suspension
Metformin Hydrochloride Extended Release Tablets
Metoprolol Succinate Extended-Release Tablets
Mycophenolic Acid DR Tablets
Nifedipine Extended-Release tablets
Paclitaxel Protein-Bound Particles for Injectable Suspension - (Albumin-Bound)
Propafenone Hydrochloride Extended-Release Capsules, USP
Sevelamer Carbonate Tablets
Sorafenib Tablets, USP
Testosterone Gel, 1.62% CIII
Terbutaline Sulfate tablets
Testosterone Topical Solution CIII, USP
Home > Products > For the United States
Mycophenolic Acid DR Tablets
Route
Oral
Dosage form
Tablet, Delayed Release
Strength
180mg and 360mg
Rx/OTC
Rx
Indication
Antimetabolite immunosuppressant indicated for prophylaxis of organ rejection.
TE Rating
AB
Reference Listed Drug
Myfortic®
ANDA#
A214289
Mycophenolate Risk Evaluation and Mitigation Strategy (REMS)
Strength
Form
Product Description
Imprint
Image
How Supplied
NDC Number
HDMA
Sheets
PI
SDS
180mg
Tablets
White film-coated round tablet with "T160" imprinted on one side
T160
120s
24979-160-44
360mg
Tablets
Orange film-coated ovaloid tablet and "T161" debossed on one side
T161
120s
24979-161-44
Back
Top